Journal of oncology research and therapy最新文献_第4页

Sentinel Lymph Node Biopsy in Breast Cancer: Past, Present, and Future 乳腺癌前哨淋巴结活检:过去，现在和未来

Journal of oncology research and therapy Pub Date : 2023-07-29 DOI: 10.29011/2574-710x.10178

引用次数: 1

Pneumomediastinum Secondary to a Major Response to Nivolumab in Mesothelioma 间皮瘤患者对纳武单抗的主要反应继发于纵隔气肿

Journal of oncology research and therapy Pub Date : 2023-07-24 DOI: 10.29011/2574-710x.10176

M. S. Moyano, D. G. Antonio

{"title":"Pneumomediastinum Secondary to a Major Response to Nivolumab in Mesothelioma","authors":"M. S. Moyano, D. G. Antonio","doi":"10.29011/2574-710x.10176","DOIUrl":"https://doi.org/10.29011/2574-710x.10176","url":null,"abstract":"Introduction: Malignant pleural mesothelioma (MPM) is a rare entity associated with chronic asbestos exposure. Second-line immunotherapy (IT) treatment is associated with very limited benefit, although in selected patients, durable partial responses have been reported. Material and methods: This case describes the evolution of a patient with MPM undergoing palliative pleurodesis at diagnosis who received second-line Nivolumab monotherapy at the Department of Medical Oncology of the Hospital Universitario Infanta Sofia and follow-up at the Department of Thoracic Surgery of the Hospital Universitario Puerta de Hierro. Results: We describe the case of an 83-year-old patient diagnosed with MPM who, after palliative pleurodesis at diagnosis and 4 cycles of platinum-based chemotherapy, had an excellent response to Nivolumab monotherapy. As a consequence of this good response, he presented a pneumomediastinum and subcutaneous emphysema without pneumothorax when a mediastinal-pleural communication developed. Management was conservative and the patient, six months after discontinuation of treatment, is in response with complete resolution of this complication. Conclusion: This case shows a dramatic response to second-line Nivolumab in advanced MPM with the development of a pneumomediastinum as a resultant complication. This finding has not been previously described in the literature.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75293246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Neurological Safety Profile in the Use of Checkpoint Inhibitors: A Real-World Evidence Approach Based on Pharmacovigilance Data 使用检查点抑制剂的神经系统安全性评估:基于药物警戒数据的真实世界证据方法

Journal of oncology research and therapy Pub Date : 2023-07-24 DOI: 10.29011/2574-710x.10177

A. Abrahao, Tenorio PHM², M. Rodrigues, Osvaldo J. M. do Nascimento¹, O. Nascimento

{"title":"Evaluation of Neurological Safety Profile in the Use of Checkpoint Inhibitors: A Real-World Evidence Approach Based on Pharmacovigilance Data","authors":"A. Abrahao, Tenorio PHM², M. Rodrigues, Osvaldo J. M. do Nascimento¹, O. Nascimento","doi":"10.29011/2574-710x.10177","DOIUrl":"https://doi.org/10.29011/2574-710x.10177","url":null,"abstract":"The use of immunotherapies based on the concept of checkpoint inhibitors is increasingly becoming a medical practice in oncology. These therapies target some specific factors, inhibiting them, blocking them to stop the multiplication of these altered cells and consequently the tumor. This study focused on the neurological safety profile of the most prescribed checkpoint inhibitors and traced a correlation between the use of these agents and the increase in neurological adverse events in the main indications. Examining pharmacovigilance databases and medication sales, the analysis found a correlation between reported neurological adverse events and medication usage. As the total number of adverse events increased, the number of neurological adverse events also rose linearly, emphasizing the importance of monitoring potential neurological effects. For the analysis of adverse event data, the databases of FDA (FAERS) and EMA (VigiAccess) were consulted, while sales data between 2018 and 2022 were extracted from the IQVIA Analytics databases. Among the studied checkpoint inhibitors (pembrolizumab, ipilimumab, nivolumab, atezolizumab, and avelumab), pembrolizumab had the lowest ratio of reported adverse events, suggesting a relatively safer profile.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87297971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distant Metastasis to Genital Organs in Infiltrating Ductal Carcinoma of the Breast in a Young Patient 年轻乳腺浸润性导管癌远处转移至生殖器官1例

Journal of oncology research and therapy Pub Date : 2023-06-26 DOI: 10.29011/2574-710x.10174

引用次数: 0

Health Literacy and Oral Oncology study on the HPV Risk Factor in a Portuguese University 健康素养和口腔肿瘤对葡萄牙大学HPV危险因素的研究

Journal of oncology research and therapy Pub Date : 2023-06-23 DOI: 10.29011/2574-710x.10173

Augusta Silveira, P. Ferreira, M. Vieira, Samuel Andrade, Clara Mancelos, T. Sequeira

引用次数: 0

SIRT2 Suppression Increases Responsiveness of Glioma Cells to Radiation Treatment via FoxO3a Inhibition SIRT2抑制通过FoxO3a抑制提高胶质瘤细胞对放射治疗的反应性

Journal of oncology research and therapy Pub Date : 2023-05-23 DOI: 10.29011/2574-710x.10171

Zhihan Wang, Jianyi Zhao, Wenrui Zhang, Keman Liao, Hao Xu, Zilong Wei, Li Ren

{"title":"SIRT2 Suppression Increases Responsiveness of Glioma Cells to Radiation Treatment via FoxO3a Inhibition","authors":"Zhihan Wang, Jianyi Zhao, Wenrui Zhang, Keman Liao, Hao Xu, Zilong Wei, Li Ren","doi":"10.29011/2574-710x.10171","DOIUrl":"https://doi.org/10.29011/2574-710x.10171","url":null,"abstract":"Due to the resistance to radiotherapy, the prognosis of patients with glioblastoma multiforme (GBM) is poor despite standard treatment. Forkhead Box O3 (FoxO3a) is reported to mediate multiple pathological processes involved in proliferation, apoptosis, and DNA repair processes, and associated with poor prognosis of GBM. Further work is required to explore the role of FoxO3a in GBM radioresistance. RT-qPCR indicated that FoxO3a was significantly up-regulated in GBM cells in response to radiation. Knockdown of FoxO3a enhances the responsiveness of GBM cells to radiotherapy. After radiation stimulation, the clonogenic capacity of the cells with FoxO3a knockdown (KD) was much weaker than that of the normal control group (NC), while the degree of DNA damage detected by the comet assay was significantly higher in the cells with FoxO3a knockdown. Moreover, combining recent research, we demonstrated that suppression of SIRT2 down-regulated FoxO3a with radiation therapy by Western Blot. DNA damage assay and comet assay indicated that the degree of DNA damage increased in the cells of SIRT2 knockdown compared to the normal control (NC). The study indicated that suppression of SIRT2 increased the sensitivity of GBM cells to radiotherapy via FoxO3a inhibition and provided a novel idea for overcoming radioresistance in GBM.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75699966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Involvement of Exportin 1 Mediated c-Myc and Cullin 4A Signaling in Apoptotic Effect of Fisetin in Non-small Cell Lung Cancer Cells 输出蛋白1介导的c-Myc和Cullin 4A信号通路参与非西汀对非小细胞肺癌细胞凋亡的影响

Journal of oncology research and therapy Pub Date : 2023-05-06 DOI: 10.29011/2574-710x.10169

Joe Young, Hyemin Lee, Ji Eon, P. Deok, Yong Sim, Hyo-Jung Lee, Chi-Hoon Ahn, Su Yeon Park, B. Shim, Bonglee Kim, Sung-Hoon Kim

引用次数: 0

Journal of oncology research and therapy Pub Date : 2023-05-05 DOI: 10.29011/2574-710x.10168

C. Yi, J. Yang, Jianhao Hong, Ting Zhang, Liu Qin, Ying, Zhang, Dongjuan Chen

引用次数: 0

Assessment of Patient’s Knowledge about their Cancer Diagnosis and Stage of their Disease and its Implications 评估病人对其癌症诊断和疾病分期的知识及其意义

Journal of oncology research and therapy Pub Date : 2023-04-29 DOI: 10.29011/2574-710x.10167

引用次数: 0

The Discordance between Patient- and Clinician Reported Outcomes during (Chemo-) Radiation Therapy for Lung Cancer 肺癌(化疗)放射治疗期间患者和临床医生报告结果之间的不一致

Journal of oncology research and therapy Pub Date : 2023-04-29 DOI: 10.29011/2574710x.10166

引用次数: 0